

# William Rosenberg or W W Rosenberg C

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3703767/publications.pdf>

Version: 2024-02-01

116  
papers

6,858  
citations

117453

34  
h-index

60497

81  
g-index

123  
all docs

123  
docs citations

123  
times ranked

7779  
citing authors

#	ARTICLE	IF	CITATIONS
1	Towards collaborative management of non-alcoholic fatty liver disease: a "real-world" pathway for fibrosis risk assessment in primary care. <i>Internal Medicine Journal</i> , 2022, 52, 1749-1758.	0.5	3
2	Identification of liver disease: why and how. <i>Frontline Gastroenterology</i> , 2022, 13, 367-373.	0.9	12
3	A rational approach to improving titer in Escherichia coli-based cell-free protein synthesis reactions. <i>Biotechnology Progress</i> , 2021, 37, e3062.	1.3	9
4	Systematic review: Investigating the prognostic performance of four non-invasive tests in alcohol-related liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1435-1449.	1.4	7
5	P210...Enhanced-liver-fibrosis score was not influenced by alcohol consumption in a patient cohort with alcohol-use-disorders. , 2021, , .		0
6	Escherichia coli-Based Cell-Free Protein Synthesis for Iterative Design of Tandem-Core Virus-Like Particles. <i>Vaccines</i> , 2021, 9, 193.	2.1	3
7	Relationship of ELF and PIIINP With Liver Histology and Response to Vitamin E or Pioglitazone in the PIVENS Trial. <i>Hepatology Communications</i> , 2021, 5, 786-797.	2.0	12
8	Uncovering unsuspected advanced liver fibrosis in patients referred to alcohol nurse specialists using the ELF test. <i>BMC Gastroenterology</i> , 2021, 21, 143.	0.8	3
9	Optimising referral pathways for patients with non-alcoholic fatty liver disease in the UK. <i>British Journal of Health Care Management</i> , 2021, 27, 62-70.	0.1	1
10	Circulating Macrophage Activation Markers Predict Transplant-Free Survival in Patients With Primary Sclerosing Cholangitis. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00315.	1.3	10
11	Systematic review: Accuracy of the enhanced liver fibrosis test for diagnosing advanced liver fibrosis and cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1788-1802.	1.4	16
12	The Enhanced Liver Fibrosis test maintains its diagnostic and prognostic performance in alcohol-related liver disease: a cohort study. <i>BMC Gastroenterology</i> , 2021, 21, 268.	0.8	8
13	Is there scope to improve the selection of patients with alcohol-related liver disease for referral to secondary care? A retrospective analysis of primary care referrals to a UK liver centre, incorporating simple blood tests. <i>BMJ Open</i> , 2021, 11, e047786.	0.8	7
14	Relationship of Enhanced Liver Fibrosis Score with Pediatric Nonalcoholic Fatty Liver Disease Histology and Response to Vitamin E or Metformin. <i>Journal of Pediatrics</i> , 2021, 239, 161-167.e5.	0.9	8
15	Fluctuating biomarkers in primary sclerosing cholangitis: A longitudinal comparison of alkaline phosphatase, liver stiffness, and ELF. <i>JHEP Reports</i> , 2021, 3, 100328.	2.6	8
16	Reply to: "FIB-4 cut-off should be re-evaluated in patients with metabolic associated fatty liver disease (MAFLD)". <i>Journal of Hepatology</i> , 2021, 74, 248-249.	1.8	0
17	P211...Alcohol use disorders and liver fibrosis " cases are missed through failure to test. , 2021, , .		0
18	O75...Training in clinical research for the any, not the few: a pilot programme in hepatology. , 2021, , .		0

#	ARTICLE	IF	CITATIONS
19	A review of the clinical utility of the Enhanced Liver Fibrosis test in multiple aetiologies of chronic liver disease. <i>Annals of Clinical Biochemistry</i> , 2020, 57, 36-43.	0.8	5
20	Human Liver Memory CD8+ T Cells Use Autophagy for Tissue Residence. <i>Cell Reports</i> , 2020, 30, 687-698.e6.	2.9	53
21	Reply to: "FIB-4 cut off of 1.3 may be inappropriate in a primary care referral pathway for patients with non-alcoholic fatty liver disease". <i>Journal of Hepatology</i> , 2020, 73, 217-218.	1.8	1
22	The Enhanced Liver Fibrosis test is associated with liver-related outcomes in postmenopausal women with risk factors for liver disease. <i>BMC Gastroenterology</i> , 2020, 20, 104.	0.8	5
23	Detection, stratification and treatment of hepatitis C "positive prisoners in the United Kingdom prison estate: Development of a pathway of care to facilitate the elimination of hepatitis C in a London prison. <i>Journal of Viral Hepatitis</i> , 2020, 27, 987-995.	1.0	11
24	Inflammation and fibrosis in chronic liver diseases including non-alcoholic fatty liver disease and hepatitis C. <i>World Journal of Gastroenterology</i> , 2020, 26, 109-133.	1.4	110
25	Decompensated cirrhosis is the commonest presentation for NAFLD patients undergoing liver transplant assessment. <i>Clinical Medicine</i> , 2020, 20, 313-318.	0.8	14
26	Errors in modeling misrepresent the utility of the enhanced liver fibrosis test in the management of non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2020, 73, 1580-1581.	1.8	3
27	FRI-202-Outcomes of hepatitis B patients transplanted without hepatitis B immunoglobulin. <i>Journal of Hepatology</i> , 2019, 70, e480.	1.8	0
28	Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease. <i>BMC Gastroenterology</i> , 2019, 19, 122.	0.8	81
29	Referral pathways for patients with NAFLD based on non-invasive fibrosis tests: Diagnostic accuracy and cost analysis. <i>Liver International</i> , 2019, 39, 2052-2060.	1.9	49
30	FRI-132-In vitro modulation by TLR8 agonist GS-9688 of multiple regulatory cell types in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2019, 70, e445.	1.8	2
31	PS-078-A phase 1b evaluation of HepTcell HBV-specific immunotherapy in nuc-controlled, eAg negative chronic HBV infection. <i>Journal of Hepatology</i> , 2019, 70, e50-e51.	1.8	13
32	SAT-412-The utility of the enhanced liver fibrosis test in alcoholic liver disease. <i>Journal of Hepatology</i> , 2019, 70, e815.	1.8	1
33	The association between hepatocellular carcinoma and direct-acting anti-viral treatment in patients with decompensated cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 204-214.	1.9	20
34	Understanding how, why, for whom, and under what circumstances opt-out blood-borne virus testing programmes work to increase test engagement and uptake within prison: a rapid-realist review. <i>BMC Health Services Research</i> , 2019, 19, 152.	0.9	17
35	Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2019, 71, 371-378.	1.8	301
36	Epitope Presentation of Dengue Viral Envelope Glycoprotein Domain III on Hepatitis B Core Protein Virus-Like Particles Produced in <i>Nicotiana benthamiana</i> . <i>Frontiers in Plant Science</i> , 2019, 10, 455.	1.7	18

#	ARTICLE	IF	CITATIONS
37	Cholangiocarcinoma is associated with a raised enhanced liver fibrosis score independent of primary sclerosing cholangitis. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13088.	1.7	14
38	PTU-029...Decompensated cirrhosis is the commonest presentation for NAFLD patients undergoing liver transplant assessment. , 2019, , .		0
39	PTU-032...Alcohol use disorders and liver fibrosis-can we improve the referral pathway to secondary care?. , 2019, , .		0
40	Derivation and Performance of Standardized Enhanced Liver Fibrosis (ELF) Test Thresholds for the Detection and Prognosis of Liver Fibrosis. <i>Journal of Applied Laboratory Medicine</i> , The, 2019, 3, 815-826.	0.6	45
41	Comparison and correlation of fibrosis stage assessment by collagen proportionate area (CPA) and the ELF panel in patients with chronic liver disease. <i>Digestive and Liver Disease</i> , 2019, 51, 1001-1007.	0.4	13
42	Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial. <i>Hepatology</i> , 2018, 67, 2113-2126.	3.6	22
43	Persistence of hepatocellular carcinoma risk in hepatitis C patients with a response to <scp>IFN</scp> and cirrhosis regression. <i>Liver International</i> , 2018, 38, 1459-1467.	1.9	22
44	A virus-like particle vaccine candidate for influenza A virus based on multiple conserved antigens presented on hepatitis B tandem core particles. <i>Vaccine</i> , 2018, 36, 873-880.	1.7	31
45	The enhanced liver fibrosis (ELF) test in diagnosis and management of liver fibrosis. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2018, 79, 694-699.	0.2	22
46	A Pragmatic Approach Identifies a High Rate of Nonalcoholic Fatty Liver Disease With Advanced Fibrosis in Diabetes Clinics and At-Risk Populations in Primary Care. <i>Hepatology Communications</i> , 2018, 2, 897-909.	2.0	54
47	A Rapid and Robust Diagnostic for Liver Fibrosis Using a Multichannel Polymer Sensor Array. <i>Advanced Materials</i> , 2018, 30, e1800634.	11.1	62
48	Applying Unique Molecular Identifiers in Next Generation Sequencing Reveals a Constrained Viral Quasispecies Evolution under Cross-Reactive Antibody Pressure Targeting Long Alpha Helix of Hemagglutinin. <i>Viruses</i> , 2018, 10, 148.	1.5	4
49	Methods for the evaluation of biomarkers in patients with kidney and liver diseases: multicentre research programme including ELUCIDATE RCT. <i>Programme Grants for Applied Research</i> , 2018, 6, 1-528.	0.4	3
50	Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study. <i>Liver International</i> , 2017, 37, 1554-1561.	1.9	54
51	T Cells Infiltrating Diseased Liver Express Ligands for the NKG2D Stress Surveillance System. <i>Journal of Immunology</i> , 2017, 198, 1172-1182.	0.4	41
52	Biomarkers of Hepatic Fibrosis in Chronic Hepatitis C. <i>Journal of Clinical Gastroenterology</i> , 2017, 51, 268-277.	1.1	14
53	Elbasvir/Grazoprevir Plus Sofosbuvir in Treatment-Naive and Treatment-Experienced Cirrhotic Patients with Hepatitis C Virus Genotype 3 Infection Treated for 8, 12 or 16 Weeks: Final Results of the C-ISLE Study. <i>Gastroenterology</i> , 2017, 152, S1061.	0.6	3
54	Risk of chronic liver disease in post-menopausal women due to body mass index, alcohol and their interaction: a prospective nested cohort study within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>BMC Public Health</i> , 2017, 17, 603.	1.2	11

#	ARTICLE	IF	CITATIONS
55	Production and purification of chimeric HBc virus-like particles carrying influenza virus LAH domain as vaccine candidates. BMC Biotechnology, 2017, 17, 79.	1.7	26
56	The Enhanced Liver Fibrosis (ELF) Panel: Analyte Stability Under Common Sample Storage Conditions Used in Clinical Practice. journal of applied laboratory medicine, The, 2017, 1, 720-728.	0.6	8
57	Prospective Validation of the Enhanced Liver Fibrosis (ELF) Test for the Prediction of Disease Progression in a Randomized Trial of Patients with Primary Sclerosing Cholangitis (PSC). Gastroenterology, 2017, 152, S1060.	0.6	0
58	Serological Tests Do Not Predict Residual Fibrosis in Hepatitis C Cirrhotics with a Sustained Virological Response to Interferon. PLoS ONE, 2016, 11, e0155967.	1.1	23
59	Enhanced liver fibrosis marker as a noninvasive predictor of mortality in HIV/hepatitis C virus-coinfected women from a multicenter study of women with or at risk for HIV. Aids, 2016, 30, 723-729.	1.0	12
60	Isolated Hepatitis B Core Antibody Status Is Not Associated With Accelerated Liver Disease Progression in HIV/Hepatitis C Coinfection. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, 274-280.	0.9	5
61	Association of HIV, Hepatitis C Virus, and Liver Fibrosis Severity With the Enhanced Liver Fibrosis Score. Journal of Infectious Diseases, 2016, 213, 1079-1086.	1.9	18
62	IL28B genotype predicts response to chronic hepatitis C triple therapy with telaprevir or boceprevir in treatment naïve and treatment-experienced patients other than prior partial- and null-responders. SpringerPlus, 2015, 4, 357.	1.2	8
63	Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis. Hepatology, 2015, 62, 188-197.	3.6	106
64	Tandem Fusion of Hepatitis B Core Antigen Allows Assembly of Virus-Like Particles in Bacteria and Plants with Enhanced Capacity to Accommodate Foreign Proteins. PLoS ONE, 2015, 10, e0120751.	1.1	105
65	Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. New England Journal of Medicine, 2015, 373, 2608-2617.	13.9	740
66	Equilibrium Contrast-enhanced CT Imaging to Evaluate Hepatic Fibrosis: Initial Validation by Comparison with Histopathologic Sampling. Radiology, 2015, 275, 136-143.	3.6	77
67	Hepatitis delta virus testing, epidemiology and management: A multicentre cross-sectional study of patients in London. Journal of Clinical Virology, 2015, 66, 33-37.	1.6	39
68	Metabolic Phenotyping for Enhanced Mechanistic Stratification of Chronic Hepatitis C-Induced Liver Fibrosis. American Journal of Gastroenterology, 2015, 110, 159-169.	0.2	29
69	Complexities of HCV management in the new era of direct-acting antiviral agents. QJM - Monthly Journal of the Association of Physicians, 2014, 107, 17-19.	0.2	5
70	Evaluation of the Aspartate Aminotransferase/Platelet Ratio Index and Enhanced Liver Fibrosis Tests to Detect Significant Fibrosis Due to Chronic Hepatitis C. Journal of Clinical Gastroenterology, 2014, 48, 370-376.	1.1	23
71	Telaprevir or boceprevir based therapy for chronic hepatitis C infection: Development of resistance-associated variants in treatment failure. Antiviral Research, 2014, 105, 112-117.	1.9	11
72	The enhanced liver fibrosis test: a clinical grade, validated serum test, biomarker of overall fibrosis in systemic sclerosis. Annals of the Rheumatic Diseases, 2014, 73, 420-427.	0.5	37

#	ARTICLE	IF	CITATIONS
73	Prediction of liver disease in patients whose liver function tests have been checked in primary care: model development and validation using population-based observational cohorts. <i>BMJ Open</i> , 2014, 4, e004837-e004837.	0.8	24
74	Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality. <i>BMC Gastroenterology</i> , 2014, 14, 137.	0.8	34
75	Fibrosis biomarkers in isolated Raynaud's phenomenon: too little, too soon?. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 940-941.	0.5	11
76	Treatment decisions and contemporary versus pending treatments for hepatitis C. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 713-728.	8.2	17
77	Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2013, 57, 103-111.	3.6	103
78	The Third Signal Cytokine IL-12 Rescues the Anti-Viral Function of Exhausted HBV-Specific CD8 T Cells. <i>PLoS Pathogens</i> , 2013, 9, e1003208.	2.1	176
79	The Diversity and Management of Chronic Hepatitis B Virus Infections in the United Kingdom: A Wake-up Call. <i>Clinical Infectious Diseases</i> , 2013, 56, 951-960.	2.9	35
80	Biopsy-Controlled Liver Fibrosis Staging Using the Enhanced Liver Fibrosis (ELF) Score Compared to Transient Elastography. <i>PLoS ONE</i> , 2012, 7, e51906.	1.1	29
81	Randomized clinical trial. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 543-550.	0.8	6
82	Predicted Effects of Treatment for HCV Infection Vary Among European Countries. <i>Gastroenterology</i> , 2012, 143, 974-985.e14.	0.6	107
83	Upregulation of the Tim-3/Galectin-9 Pathway of T Cell Exhaustion in Chronic Hepatitis B Virus Infection. <i>PLoS ONE</i> , 2012, 7, e47648.	1.1	235
84	The Utility of Liver Function Tests for Mortality Prediction within One Year in Primary Care Using the Algorithm for Liver Function Investigations (ALFI). <i>PLoS ONE</i> , 2012, 7, e50965.	1.1	12
85	A Combination of the Pediatric NAFLD Fibrosis Index and Enhanced Liver Fibrosis Test Identifies Children With Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 150-155.e1.	2.4	90
86	Role of a cirrhosis risk score for the early prediction of fibrosis progression in hepatitis C patients with minimal liver disease. <i>Journal of Hepatology</i> , 2011, 55, 38-44.	1.8	51
87	Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis. <i>BMC Gastroenterology</i> , 2010, 10, 103.	0.8	117
88	Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. <i>Gut</i> , 2010, 59, 1245-1251.	6.1	273
89	Psychosocial Aspects of DNA Testing for Hereditary Hemochromatosis in At-Risk Individuals: A Systematic Review. <i>Genetic Testing and Molecular Biomarkers</i> , 2009, 13, 7-14.	0.3	13
90	Health outcomes following liver function testing in primary care: a retrospective cohort study. <i>Family Practice</i> , 2009, 26, 251-259.	0.8	23

#	ARTICLE	IF	CITATIONS
91	Recombinant <i>Ov</i> -ASP-1, a Th1-Biased Protein Adjuvant Derived from the Helminth <i>Onchocerca volvulus</i> , Can Directly Bind and Activate Antigen-Presenting Cells. <i>Journal of Immunology</i> , 2009, 182, 4005-4016.	0.4	35
92	Performance of ELF Serum Markers in Predicting Fibrosis Stage in Pediatric Non-Alcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2009, 136, 160-167.	0.6	233
93	Psychosocial Aspects of DNA Testing for Hereditary Hemochromatosis in At-Risk Individuals: A Systematic Review. <i>Genetic Testing and Molecular Biomarkers</i> , 2009, .	1.7	0
94	Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. <i>Hepatology</i> , 2008, 47, 455-460.	3.6	625
95	Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. <i>Hepatology</i> , 2008, 48, 1549-1557.	3.6	167
96	Development of a decision support tool to facilitate primary care management of patients with abnormal liver function tests without clinically apparent liver disease [HTA03/38/02]. Abnormal Liver Function Investigations Evaluation (ALFIE). <i>BMC Health Services Research</i> , 2007, 7, 54.	0.9	13
97	Haemochromatosis. <i>Medicine</i> , 2007, 35, 89-92.	0.2	5
98	Performance of serum marker panels for liver fibrosis in chronic hepatitis C. <i>Journal of Hepatology</i> , 2006, 44, 462-474.	1.8	217
99	Variation in Hepatitis C services may lead to inequity of health-care provision: a survey of the organisation and delivery of services in the United Kingdom. <i>BMC Public Health</i> , 2006, 6, 3.	1.2	33
100	Comparison of genotypic and phenotypic strategies for population screening in hemochromatosis: Assessment of anxiety, depression, and perception of health. <i>Genetics in Medicine</i> , 2005, 7, 550-556.	1.1	21
101	Factors affecting the uptake of screening: A randomised controlled non-inferiority trial comparing a genotypic and a phenotypic strategy for screening for haemochromatosis. <i>Journal of Hepatology</i> , 2005, 43, 149-155.	1.8	15
102	Haemochromatosis: the need for an agreed case definition. <i>Journal of Hepatology</i> , 2005, 43, 911.	1.8	6
103	CD44 isoform expression on colonic epithelium mediates lamina propria lymphocyte adhesion and is controlled by Th1 and Th2 cytokines. <i>European Journal of Gastroenterology and Hepatology</i> , 2003, 15, 1101-1110.	0.8	15
104	Diaries of evidence-based tutors: beyond "numbers needed to teach".... <i>Journal of Evaluation in Clinical Practice</i> , 2000, 6, 149-154.	0.9	6
105	Immune selection and genetic sequence variation in core and envelope regions of hepatitis C virus. <i>Hepatology</i> , 1999, 30, 1037-1044.	3.6	53
106	Rapid mapping of markers applying vectorette technology to YAC fragmentation allows easy assembly of a high-density STS bacterial clone contig spanning the markers D6S1260-D6S1918. <i>Mammalian Genome</i> , 1998, 9, 220-225.	1.0	1
107	More microsatellite markers around D6S105. <i>Molecular and Cellular Probes</i> , 1998, 12, 181-184.	0.9	0
108	Evidence-based Medicine and Child Mental Health Services. A Broad Approach to Evaluation is Needed. <i>Children and Society</i> , 1997, 11, 89-96.	1.0	4

#	ARTICLE	IF	CITATIONS
109	How to Use Overviews of Prevention Trials to Treat Individual Patients. <i>Cerebrovascular Diseases</i> , 1996, 6, 34-40.	0.8	3
110	An HLA-B35-restricted epitope modified at an anchor residue results in an antagonist peptide. <i>European Journal of Immunology</i> , 1996, 26, 335-339.	1.6	46
111	CD44v6 and CD44v3 expression in ulcerative colitis and Crohn's disease. <i>Lancet, The</i> , 1995, 346, 256.	6.3	2
112	Evidence based medicine: an approach to clinical problem-solving. <i>BMJ: British Medical Journal</i> , 1995, 310, 1122-1126.	2.4	917
113	Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants. <i>Nature</i> , 1994, 369, 403-407.	13.7	438
114	A sequence pattern for peptides presented to cytotoxic T lymphocytes by HLA B8 revealed by analysis of epitopes and eluted peptides. <i>European Journal of Immunology</i> , 1993, 23, 447-453.	1.6	105
115	An antigen processing polymorphism revealed by HLA-B8-restricted cytotoxic T lymphocytes which does not correlate with TAP gene polymorphism. <i>European Journal of Immunology</i> , 1993, 23, 1999-2004.	1.6	32
116	An entropic safety catch controls hepatitis C virus entry and antibody resistance. <i>ELife</i> , 0, 11, .	2.8	7